Navigation Links
Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Date:11/29/2007

VYVANSE were decreased appetite, difficulty falling asleep, stomachache, and irritability.

Aggression, new abnormal thoughts/behaviors, mania, growth suppression, worsening of motion or verbal tics, and Tourette's syndrome have been associated with use of drugs of this type. Tell the doctor if your child has blurred vision while taking VYVANSE.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.

Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's Web site: http://www.shire.com.

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGFbeta3) and GA-GCB (velaglucerase alfa); manufactu
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , October 1, 2014 ... Next Generation Sequencing (NGS) data analysis, today launches a ... cystic fibrosis analysis in a single NGS experiment. The ... all types of variants in a single NGS experiment ... it has not been possible to simultaneously analyse all ...
(Date:9/30/2014)... MARIETTA, Ga. , Sept. 30, 2014 ... leading regenerative medicine company utilizing human amniotic tissue and ... therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports ... Dr. Tom Koob , Ph.D., Chief Scientific Officer, ... Mesa. Dr. Koob will present on Tuesday, October 7, ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Aileron Therapeutics, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
Breaking Medicine Technology:Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2MiMedx to Present at the Stem Cell Meeting on the Mesa 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
... At the 10th Asian Forum on Corporate Responsibility ... and its philanthropic foundation the Abbott Fund were honored ... advancing science education in the region.  Abbott Science Education ... innovative events designed to spark an interest in life-long ...
... Mass. and TORONTO, Oct. 24, 2011 Generex Biotechnology ... the Company is planning an investor update conference call ... to provide investors with an update on (i) the ... previously announced spinout of its wholly-owned immunotherapeutics subsidiary, Antigen ...
Cached Medicine Technology:Abbott Honored With Asian CSR Award for Leadership in Science Education 2Abbott Honored With Asian CSR Award for Leadership in Science Education 3Generex Announces Investor Update Conference Call Planned for Late November 2Generex Announces Investor Update Conference Call Planned for Late November 3
(Date:10/2/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... major highway may raise your risk for high blood pressure, ... women, those who lived within 109 yards of a busy ... blood pressure than women living at least half a mile ... highlight the importance of our physical environment on our health ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... the stops to rescue surgical patients in crisis are ... such heroism is questionable, a new study suggests. ... saving elderly patients with life-threatening complications after major surgery, ... senior author Dr. Amir Ghaferi. He is assistant professor ...
(Date:10/1/2014)... Adelaide have developed a model that could help to ... treatment - from their very first psychotic episode. , ... including clinical symptoms, cognitive abilities, MRI scans of the ... Speaking in the lead up to World Mental Health ... , Professor Bernhard Baune , says the model ...
(Date:10/1/2014)... study published today in the Journal of the ... than 50 years with moderate or severe chronic knee ... from the University of Melbourne randomly assigned 282 patients ... no acupuncture or sham or pretend laser treatment. ... and acupuncturists blinded to laser and sham (inactive) laser ...
(Date:10/1/2014)... PA, October 1, 2014 Patients with increased ... have a greatly increased risk of depression. For ... for chronic hepatitis C virus infection causes depression ... fatty acids, more commonly known as fish oil, ... lowering the risk of heart disease and reducing ...
Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Predicting the future course of psychotic illness 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Omega-3 fatty acids may prevent some forms of depression 2
... but critics want agency to act, not wait years ... ads on television should include a toll-free phone number ... U.S. health experts suggested Friday. , The experts serve ... Drug Administration. Such phone numbers are already mandated by ...
... Workers, WASHINGTON, May 16 More than ... Portland, Oregon and,Vancouver, Washington area have ratified their ... that these workers are now covered by a,strong ... secure retirement,future," said Teamsters General President Jim Hoffa., ...
... benefit from calcitriol, an oral form , , FRIDAY, May 16 ... risk of death for people with moderate to severe chronic ... , During a two-year study of more than 1,400 ... activated vitamin D, had their overall risk of death lowered ...
... what did you,say?" is a phrase being used more ... Americans, that is 1 in 9 individuals, have,significant hearing ... rate.,Thirteen out of every 100 school age children have ... attention to this social and economic problem,is what led ...
... for May 19 at 10:15 a.m. Eastern Time, ... (TSX: RBM, OTCBB: RPBIF) today announced that S. ... at the Rodman & Renshaw,5th Annual Global Healthcare ... A live web cast of the presentation ...
... needs is more unemployed politicians - and economists, ... health care at the top of their "most-important issues" ... health care plans,advanced by any of the current presidential ... U.S. Senate Majority Leader Bill Frist., Jousting with ...
Cached Medicine News:Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
Bard® Channel Drain...
... Used for stone manipulation ... duct. The nitinol memory wire ... its shape following extreme torsion. ... the likelihood of mucosal damage ...
Used for serial post-operative cholangiography and the placement of a wire guide to facilitate post-operative E.R.C.P. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: